Show simple item record

dc.contributor.authorSheppard, James P
dc.contributor.authorFletcher, Kate
dc.contributor.authorMcManus, Richard J
dc.contributor.authorMant, Jonathan
dc.date.accessioned2018-09-11T17:33:34Z
dc.date.available2018-09-11T17:33:34Z
dc.date.issued2014-10
dc.identifier.issn0960-1643
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/280228
dc.description.abstractBACKGROUND: Treatment for uncomplicated stage 1 hypertension is recommended in most international guidelines but there is little evidence to indicate that therapy is beneficial. AIM: To estimate the prevalence of this condition in an untreated population and the potential costs of initiating therapy in such patients. DESIGN AND SETTING: Cross-sectional study of anonymised patient records in 19 general practices in the West Midlands, UK. METHOD: Data relating to patient demographics, existing cardiovascular disease (CVD), and risk factors (blood pressure and cholesterol) were extracted from patient records. Patients with a blood pressure of 140/90-159/99 mmHg, no CVD, and <20% 10-year cardiovascular risk were classified as having uncomplicated stage 1 hypertension. Missing data were imputed. The prevalence of untreated, uncomplicated stage 1 hypertension was estimated using descriptive statistics and extrapolated using national data. The cost of achieving blood pressure control in this population was examined in a cost-impact analysis using published costs from previous studies. RESULTS: Of the 34 975 patients (aged 40-74 years) in this study, untreated, uncomplicated stage 1 hypertension was present in 2867 individuals (8.2%, 95% confidence interval [CI] = 7.9 to 8.5). This is equivalent to 1 892 519 patients in England and Wales, for whom the additional cost of controlling blood pressure, according to guidelines, was estimated at £106-229 million per annum, depending on the health professional delivering care. CONCLUSION: Untreated, uncomplicated stage 1 hypertension is relatively common, affecting 1 in 12 patients aged 40-74 years in primary care. Current international guidelines and pay-for-performance targets, if followed, will incur significant costs for a patient benefit that is debatable.
dc.description.sponsorshipThis work forms part of a larger programme on stroke prevention in primary care supported by the National Institute for Health Research (NIHR) (RP-PG-0606-1153). James P Sheppard holds a Medical Research Council Strategic Skills PostDoctoral Fellowship. Richard J McManus holds an NIHR Professorship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NHS, NIHR, or the Department of Health.
dc.format.mediumPrint
dc.languageeng
dc.publisherRoyal College of General Practitioners
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectHumans
dc.subjectCardiovascular Diseases
dc.subjectHypertension
dc.subjectAntihypertensive Agents
dc.subjectPrevalence
dc.subjectCross-Sectional Studies
dc.subjectPrimary Prevention
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectCost-Benefit Analysis
dc.subjectPrimary Health Care
dc.subjectEngland
dc.subjectFemale
dc.subjectMale
dc.subjectPractice Guidelines as Topic
dc.subjectGeneral Practice
dc.titlePrevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis.
dc.typeArticle
prism.endingPagee648
prism.issueIdentifier627
prism.publicationDate2014
prism.publicationNameBr J Gen Pract
prism.startingPagee641
prism.volume64
dc.identifier.doi10.17863/CAM.27595
dcterms.dateAccepted2014-05-30
rioxxterms.versionofrecord10.3399/bjgp14X681817
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2014-10
dc.contributor.orcidMant, Jonathan [0000-0002-9531-0268]
dc.identifier.eissn1478-5242
rioxxterms.typeJournal Article/Review
cam.issuedOnline2014-09-29


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial 4.0 International